Introduction
Colorectal cancer is the third most common cancer in humans and the fourth most frequent cause of cancer death worldwide (Jemal et al., 2005) . Despite extensive research, treatment of advanced colorectal cancer with antitumor agents is often limited by intolerable side effects or by the development of chemoresistance (Meyerhardt and Mayer, 2005; Weitz et al., 2005) . Therefore, major scientific efforts have been invested to identify tumor-specific drug targets, that is, molecules that are selectively expressed in cancerous tissues. Glutathione-S-transferases (GST) were proposed as such promising targets, as they are overexpressed in a variety of solid tumors (Townsend and Tew, 2003) . GST are phase II detoxification enzymes and conjugate the tripeptide glutathione (GSH, g-L-glutamyl-L-cysteinyl glycine) to a wide variety of endogenous metabolites, xenobiotics, and chemotherapeutics (Ishikawa and Ali-Osman, 1993, 2002; Goto et al., 1999) . Therefore, high levels of GST in tumor cells may substantially limit the efficacy of antitumor chemotherapy. In addition to their enzymatic activity, several classes of GST have non-enzymatic functions in the regulation of relevant signal-transduction pathways. Specifically, the glutathione S-transferase of the Pi class (GSTP1) has been described as an endogenous inhibitor of Jun kinase (JNK), critically involved in stress response and apoptosis (Adler et al., 1999; Villafania et al., 2000; Yin et al., 2000) . Thus, overexpression of GSTPI by solid tumors may limit the treatment of these tumors at different levels.
Small molecule inhibitors of GST have been developed in the past and validated in preclinical and clinical studies (Townsend and Tew, 2003) . These include the diuretic agent ethacrynic acid, a competitive inhibitor of several GST classes. Ethacrynic acid effectively increases the sensitivity of tumor cells to alkylating chemotherapeutics (Tew et al., 1988) and proved clinical effectiveness in a phase II trial for chronic lymphatic leukemia (Petrini et al., 1993) . However, the long-term utility of ethacrynic acid is compromised by doselimiting toxicities related to diuresis and subsequent fluid imbalances (O'Dwyer et al., 1991) . The second generation GST inhibitor TLK199 is an effective and specific inhibitor of GSTP1 and has been tested in phase I/II clinical trials in myelodysplastic syndrome (Steensma, 2010) , however, currently data on solid tumors are missing. Thus, efficient and specific targeting of GSTP1 in tumor cells requires further efforts.
Thiazolides are a novel class of anti-infective agents. Their parent compound nitazoxanide (NTZ) was initially designed as an anti-microbial drug and approved for the treatment of intestinal infections caused by Cryptosporidium, Giardia and anaerobic prokaryotes (Fox and Saravolatz, 2005; Muller et al., 2006; Muller et al., 2008a) . Despite their effective antiinfective activity thiazolides show apparently little sideeffects on host tissue. Interestingly, though, in a recent study we demonstrated that nitazoxanide and several derivatives induce apoptosis in colon cancer cells in vitro (Muller et al., 2008b) . Intriguingly, the pro-apoptotic effect was also evident in non-nitro-compounds lacking any anti-microbial activity (for example, RM4819; Muller et al., 2006 Muller et al., , 2008a suggesting different molecular targets and mechanisms for the anti-microbial effect in prokaryotes and the pro-apoptotic effect in mammalian cells. Consequently, we identified GSTP1 as a major mammalian target of thiazolides (Muller et al., 2008b) .
In this study, we investigated the underlying molecular mechanisms of thiazolide-induced apoptosis in colon cancer cells. We demonstrated that the thiazolide derivative RM4819 requires the expression and enzymatic activity of GSTP1. RM4819 caused a long-lasting activation of JNK, resulting in transcriptional upregulation of the pro-apoptotic Bcl-2 homolog Bim and Bimassociated cell death. Although RM4819 alone was a moderate inducer of apoptosis, it potently sensitized colon cancer cells for TNFa-related apoptosis-inducing ligand (TRAIL) and chemotherapy-induced apoptosis. Thus, thiazolides are effective modulators of apoptosis signaling pathways in cancer cells and therefore promising candidates for single-or multi-agent therapy of colorectal cancer. Furthermore, while GSTP1 overexpression limits the efficacy of chemotherapy in tumor cells, it represents an Achilles' heel in thiazolide-induced apoptosis.
Results

RM4819 induces apoptosis in colon cancer cell lines
We have previously shown that thiazolides induce apoptosis in the colon cancer cell line Caco2, yet were relatively ineffective in a non-transformed human foreskin fibroblast cell line (Muller et al., 2008b) . To further characterize the pro-apoptotic properties of thiazolides, we extended these studies to different colon cancer cell lines. Time-and dose-dependent DNA fragmentation was detected in Caco2 and LS174T cells upon RM4819 treatment (Figures 1a and b) . In addition, other classical features of apoptosis were found upon thiazolide treatment, such as phosphatidylserine exposure and caspase activation (data not shown). In contrast to these colon cancer cell lines, HT29 and Colo205 cells were rather resistant to RM4819-induced apoptosis ( Figures  1c and d) .
Alteration of GSTP1 expression levels affects the sensitivity to thiazolides Our previous study identified GSTP1 as a major thiazolide-binding target in Caco2 cells (Muller et al., 2008b) . Furthermore, we found that overexpression of GSTP1 sensitized HEK293T cells to thiazolide-induced apoptosis. To investigate whether tumor cells' sensitivity to thiazolides correlates with their GSTP1 levels, we determined the basal mRNA expression of GSTP1 in various colon cancer cell lines. GSTP1 was detected in all colon cancer cell lines tested. Intriguingly, the thiazolide-sensitive Caco2 cell line showed the highest expression of GSTP1, whereas significantly lower levels were detected in the resistant cell lines Colo205 and HT29 (Figure 2a ). LS174T cells expressed intermediate levels of GSTP1, but were rather sensitive to thiazolides (Figure 1b) . A similar picture was seen when total levels of intracellular GSH were analyzed (Figure 2b) .
To determine the exact role of GSTP1 in thiazolide sensitivity, we overexpressed GSTP1 in the RM4819-resistant cell line HT29, and assessed its sensitivity to RM4819. As predicted, almost no apoptosis induction upon treatment with RM4819 was observed when HT29 cells were transfected with a control vector. In marked contrast, a significant increase of cell death induction after RM4819 treatment was observed in GSTP1-overexpressing cells (Figure 2c) , indicating that the Colon cancer, GSTP1 and thiazolide-induced apoptosis D Sidler et al GSP1 expression level is a limiting factor for RM4819-induced apoptosis in these cells.
To assess the requirement of GSTP1 for thiazolideinduced apoptosis in the RM4819-sensitive cell line Caco2, GSTP1 expression was downregulated by RNA interference and sensitivity to RM4819 was analyzed. Caco2 cells constitutively expressed high levels of GSTP1 mRNA (Figures 2a and d) , which was efficiently downregulated by GSTP1-specific siRNA (Figure 2d ). Downregulation of GSTP1 in otherwise sensitive Caco2 cells resulted in a significant protection from thiazolideinduced cell death over 16 h ( Figure 2e ) and 40 h (data not shown) at high doses of RM4819.
RM4819 induces activation of mitogen-activated protein (MAP) kinases
As we had previously shown that thiazolides specifically target GSTP1, and GSTP1 regulates MAP kinase activation (Adler et al., 1999) , we assessed whether treatment of colon carcinoma cells with RM4819 leads to MAP kinase activation. Remarkably, RM4819 treatment resulted in the phosphorylation and associated activation of the MAP kinases JNK, p38 kinase and extracellular signal-regulated kinase (ERK) in RM4819-sensitive Caco2 and LS174T cells (Figure 3a) . Interestingly, the activation of all three MAP kinases was observed over several hours. The induction of JNK activation by RM4819 was confirmed using an AP-1 (Jun/Fos) luciferase reporter system. Treatment of Caco2 cells with RM4819 resulted in a substantial increase in AP-1 reporter activity, indicating JNK activation, whereas co-transfection of cells with a dominant negative form of JNK1 or treatment with JNK inhibitor completely abolished RM4819-induced AP-1 reporter activity (Figure 3b ).
RM4819-induced cell death is dependent on JNK and p38 kinase signaling MAP kinases are critical for various cellular functions, including differentiation, proliferation and apoptosis. In general, JNK and p38 kinase activities promote apoptosis, whereas ERK activity is important for cell Colon cancer, GSTP1 and thiazolide-induced apoptosis D Sidler et al survival Davis, 2000; Wagner and Nebreda, 2009 ). We therefore investigated if MAP kinase activation is important for RM4819-induced cell death. Pharmacological inhibition of JNK by a specific inhibitor almost completely blocked RM4819-induced apoptosis in Caco2 cells (Figure 4a) . Similarly, overexpression of dominant-negative JNK I protected cells from RM4819-induced death (Figure 4b ). To assess the role of other MAP kinases in thiazolide-induced cell death, JNK, p38 and MEK1-ERK were blocked by specific inhibitors and RM4819-induced apoptosis in Caco2 ( Figure 4c ) and LS174T cells (Figure 4d ) was analyzed. Interestingly, inhibition of p38 kinase desensitized the cells to a similar extend as JNK inhibition. In contrast, no such protection was observed for the MEK1-ERK inhibitor UO126.
Bim is a critical mediator of RM4819-mediated apoptosis As JNK is an important regulator of apoptosis in cancer cells (Chen and Tan, 2000; Dhanasekaran and Reddy, 2008) and regulates the expression and activation of the BH3-only molecule Bim (Lei and Davis, 2003; Putcha et al., 2003; Kuo et al., 2009) RM4819 sensitizes tumor cells to TRAIL and chemotherapeutic drugs Although inhibition of GSTP1 by specific inhibitors can directly promote apoptosis or sensitize cancer cells to other pro-apoptotic agents owing to limited detoxification (Townsend and Tew, 2003) , thiazolide-induced apoptosis required GSTP1. We thus tested whether pretreatment of cells with RM4819 sensitizes or rather desensitizes cells to triggers of the death receptor and the mitochondrial apoptosis pathway. While low doses of TRAIL or RM4819 were rather weak inducers of apoptosis as single-agents, the concurrent stimulation with both drugs lead to rapid and profound cell death in all colon cancer cell lines tested (Figures 6a and d) , even in the thiazolide-resistant cell line HT29. As we have shown above that thiazolide-induced apoptosis requires Bim (Figure 5a ), and TRAIL has been reported to activate Bid (Li et al., 1998; Ozoren and El-Deiry, 2002) , we silenced Bim and Bid in Caco2 cells using siRNA to determine their respective role in the synergistic induction of cell death by TRAIL and RM4819. Gene silencing led to a substantial reduction of Bim and Bid levels in Caco2 cells (Figure 6e ). Intriguingly, both, Bimand Bid siRNA-targeted cells were partially but significantly protected from RM4819 and TRAIL treatment, however, concomitant silencing of both molecules resulted in the strongest protection ( Figure 6f ). We next investigated if thiazolides also sensitize cancer cells to chemotherapeutic drugs. This group of apoptosis triggers is of particular interest as xenobiotics are detoxified by GSTP1 (Ruzza et al., 2009) . Low doses of cisplatin and RM4819 were rather weak inducers of apoptosis in the various colon cancer cell lines tested. However, as seen with TRAIL, concurrent treatment of cells with RM4819 and cisplatin caused a strong synergistic cell death (Figures 7a and e) . As demonstrated in HT29 cells, the sensitizing effect of RM4819 was not restricted to cisplatin, but further extended to other agents such as CPT-11 and partially also doxorubicine (Figure 7e ).
To further assess whether the synergistic induction of cell death by RM4819 and TRAIL or cisplatin could be confirmed on a biochemical level, we analyzed the effect of thiazolides on TRAIL-and cisplatin-induced cytochrome c and second mitochondria-derived activator of caspases (SMAC) release from mitochondria during apoptosis induction. Intriguingly, no or minimal release was observed after treatment with the single-agents RM4819, TRAIL or cisplatin at sub-optimal concentrations. However, combined treatment of cells with TRAIL and RM4819 caused an early release of cytochrome c at 8 h (Figure 8a ). Later on, cytochrome c release was also detectable in cisplatin plus RM4819-treated cells, and SMAC release and degradation in both treatments (Figure 8b ). This indicates that the synergistic activity of thiazolides and other apoptosis triggers can efficiently activate the mitochondrial apoptosis pathway. Colon cancer, GSTP1 and thiazolide-induced apoptosis D Sidler et al GSTP1 enzymatic activity is required for thiazolideinduced apoptosis As thiazolides required the expression of GSTP1, we assessed the role of its enzymatic activity in mediating thiazolide-induced apoptosis. A critical substrate for GST is GSH, which is used to capture and detoxify xenobiotics and radicals (Balendiran et al., 2004) . When colon cancer cells were treated with N-acetylcystein, a significant increase in total GSH levels was observed (Figure 9a) . Interestingly, although cisplatin-induced apoptosis was efficiently blocked by N-acetylcystein treatment, likely because of increased GST/GSHmediated detoxification of the cell, significantly increased cell death was observed in RM4819-treated cells. This indicates that increased GSTP1 activity enhances thiazolide-induced apoptosis or may even be a prerequisite.
We next assessed the role of GSTP1 enzymatic activity in sensitizing cells to thiazolides. Various polymorphisms in the GSTP1 allele have been described resulting in different enzymatic activities of the encoded proteins (Watson et al., 1998; McIlwain et al., 2006) . As predicted, recombinant wild-type protein (GSTP1*A) showed an increased enzymatic activity than the mutant protein (GSTP1*B) when expressed and purified as recombinant proteins (Figures 10a and b) . The wild type and mutant alleles were then cloned into mammalian In agreement with its increased enzymatic activity a higher sensitivity to RM4819 was seen with the wild-type allele (GSTP1*A) than with the mutant allele (GSTP1*B).
GSTP1 is overexpressed in colon cancer tissue
Given the important role of GSTP1 in thiazolideinduced apoptosis in colon cancer cell lines we aimed at assessing the relative expression of this enzyme in colon cancer tissue versus normal colonic tissue or tumor stroma. Tissue samples from 16 patients undergoing hemicolectomy for primary colorectal cancer were collected from the normal colonic mucosa, the tumor edge and the tumor center. When GSTP1 expression was analyzed by quantitative RT-PCR tumor tissue was found to significantly overexpress GSTP1 compared with normal colonic mucosa (Figures 11a and b) . Similarly, when GSTP1 expression was analyzed by immunohistochemistry it was hardly detectable in normal colonic epithelial cells or hepatocytes, but expressed at high levels in cholangiocytes (bile duct cells; Figures 12a and c) . In marked contrast primary colorectal tumors and metastatic tumors in the liver strongly overexpressed GSTP1, whereas tumor stroma remained negative (Figures 12b and d) .
Discussion
Resistance to cell death is one of the hallmarks of cancer (Hanahan and Weinberg, 2000) . Various types of tumors have developed different apoptosis resistance mechanism, which permit their survival under harsh conditions. In particular drug resistance of tumor cells by various mechanisms is a major problem in cancer therapy and severely limits the successful treatment of tumor patients with chemotherapeutic drugs. This phenomenon of drug resistance is also seen in colorectal tumors (Yang et al., 2009) . Given the important role of drug and apoptosis-resistance genes in the tumor development and survival, they not only represent difficult obstacles in the therapeutic treatment of cancer, but also offer novel opportunities to specifically target these tumors. Many 'tumor-specific' markers are not tumor-restricted, but are also expressed by normal tissue cells or, on the other hand, are downregulated in certain subsets of tumor to escape targeted treatment. In contrast, drug and apoptosis resistance genes represent interesting therapeutic targets, as they are required by the tumor cells to survive and are thus unlikely to be lost or downregulated. For example, many tumors have overexpressed growth factor receptors, and their continuous stimulation promotes proliferation and survival. The epidermal growth factor receptor (EGFR), overexpressed in many colorectal tumors, is efficiently targeted with cetuximab, a monoclonal anti-EGFR antibody, leading to apoptosis of EGFR-expressing tumor cells (Garrett and Eng, 2011) . GST have a critical role in the detoxification of the cell from xenobiotics and radicals. Not surprisingly, Figure 10 GSTP1 enzymatic activity is required for RM4819-induced apoptosis. Recombinant GSTP1*A and *B proteins were purified from E. coli by affinity chromatography, and purity was assessed by gel electrophoresis and Coomassie staining (a). Their enzymatic activity was determined in vitro as described previously (Muller et al., 2008b) (Townsend and Tew, 2003; Ruzza et al., 2009) , where they severely limit the antitumor therapy by conventional chemotherapeutic drugs. In agreement with this notion we have seen here that GSTP1 is strongly overexpressed in colorectal tumors (Figures 11 and 12) and that overexpression of GSTP1 protects cells from chemotherapeutic drug-induced apoptosis (Muller et al., 2008b) . Given the important role of GSTP1 in detoxifying and protecting tumor cells from chemotherapeutic drugs, different GST and more specifically GSTP1 inhibitors have been developed with the aim to reduce detoxification and increase the sensitivity of tumors to chemotherapeutic drugs. Although ethacrynic acid has good GST inhibiting properties and sensitizes tumor cells to apoptosis, its clinical use is severely hampered by its strong diuretic action (O'Dwyer et al., 1991) . A more specific GSTP1 inhibitor TLK199 is currently being tested in the clinics (Steensma, 2010) , but data on solid tumors are missing. The basis of these therapies is, however, the same, that is, inhibition of GSTP1 and increased sensitivity of tumor cells to apoptosis. The concept of thiazolide-induced apoptosis induction is substantially different. Our present data clearly show that (high) expression of GSTP1 and induction of GSTP1 activity by increasing GSH levels is required for thiazolide-induced apoptosis. This indicates that thiazolides are prodrugs, which become activated by GSTP1 to induce a JNK and Bim-dependent apoptosis pathway. Thus, the higher the expression of GSTP1, the more resistant tumor cells become to chemotherapy and the more sensitive to thiazolides, revealing GSTP1 as an Achilles' heel of thiazolideinduced apoptosis. Our data show a good correlation between GSTP1 expression and intracellular GSH levels and sensitivity to thiazolides. Furthermore, we also observed that, although RM4819 alone was a relatively weak and slow inducer of apoptosis in colorectal cancer cell lines (Figure 1) , it strongly synergized with TRAIL and cisplatin in inducing tumor cell apoptosis (Figures 6  and 7 ). This is in as much surprising as thiazolideinduced apoptosis is promoted by GSTP1, whereas cisplatin-induced death is prevented by GSTP1. Furthermore, the combination of thiazolides and TRAIL or cisplatin promoted extensive cell death even in cell lines otherwise resistant to thiazolides, that is, Colo205 and HT29. Thus, the simultaneous engagement of multiple apoptosis-signaling pathway strongly sensitizes cells to apoptosis and offers an increased therapeutic window.
GSTP1 and also other GST have been reported to control apoptosis induction by at least two mechanisms. Although their enzymatic activity is important for detoxification and thus limiting the effect of chemotherapeutic drugs, they also block apoptosis by sequestering critical signaling molecules. For example, GSTP1 has Colon cancer, GSTP1 and thiazolide-induced apoptosis D Sidler et al been shown to bind JNK, p38 and TRAF2 and limit their activity upon stimulation by specific signals (Adler et al., 1999; Yin et al., 2000; Townsend and Tew, 2003) . Thus, GSTP1-deficient mice show increased basal JNK and TRAF2 activation (Elsby et al., 2003) . Interestingly, this latter activity of GSTP1 seems not to be dependent on its enzymatic activity (Adler et al., 1999; Yin et al., 2000) . Along these lines we observed strong thiazolideinduced activation of JNK and p38, and JNK-and p38-dependent cell death. This could mean that thiazolides inhibit GSTP1 and thereby liberate JNK, and possibly also p38, from the sequestration by GSTP1. Our results, however, suggest an alternative pathway leading to the activation of MAP kinases and subsequent cell death. Unlike its role in sequestering JNK, we found that thiazolide-induced apoptosis was dependent on the enzymatic activity of GSTP1. Reduced expression of GSTP1 resulted in reduced thiazolide-induced apoptosis, whereas an increase in GSH further boosted thiazolide-induced death. Similarly, overexpression of the enzymatically more active GSTP1 allele A* (Watson et al., 1998) sensitized cells to thiazolides, whereas the enzymatically less active allele B* did not. It is thus more likely that the product of GSTP1-converted thiazolides promotes the activation of the different MAP kinase pathways, rather than via inhibition of GSTP1. Along these lines is the surprising observation that GSTP1-deficient mice develop increased numbers of intestinal tumors in the APC min/ þ model (Ritchie et al., 2009 ), rather than having reduced tumor burden. This could indicate that even in vivo GSTP1 may enzymatically convert inactive endogenous or bacterial substances to tumoricidal products, which limits the growth and development of intestinal tumors. This hypothesis, however, needs to further investigated.
As a critical downstream effector pathway of thiazolide-induced apoptosis we identified a JNK-mediated induction and activation of the pro-apoptotic Bcl-2 homolog Bim. Thiazolide-induced apoptosis was efficiently blocked by downregulating Bim or overexpressing anti-apoptositic Bcl-2 homologs, which antagonize Bim. This finding shows interesting parallels to other studies from our lab and others. We have previously identified Bim as an important molecule involved in the crosstalk between the extrinsic and the intrinsic apoptosis pathway. JNK-mediated induction and activation of Bim had a critical role in Fas-and TNF-induced liver damage (Corazza et al., 2006; Kaufmann et al., 2009) , chemotherapeutic drug-induced hepatocellular tumor cell apoptosis (Schneider-Jakob et al., 2010) , and paracetamol-induced liver damage (Badmann et al., 2011) . Thus, JNK-mediated activation of Bim and subsequent engagement of the mitochondrial apoptosis pathway seems to represent a common mechanism how primary and transformed cells are sensitized to apoptosis induction, and thus represent interesting targets of tumor therapy.
A similar mechanism of GSTP1-mediated activation of a prodrug to its active compound has been reported for TLK286, a glutathionyl conjugate of nitrogen mustard prodrug (Tew, 2005) . Its activation by GSTP1 leads to the release of active nitrogen mustard. Although well tolerated in clinical studies, no significant improvement over conventional chemotherapy alone has been observed so far. However, this study confirms the usefulness of the overall principle, that is, that tumorspecific overexpression of a drug resistance gene can be used to pharmacologically target tumors. Although thiazolides have not been tested yet in clinical studies for the treatment of colorectal tumors, its approved use in the treatment of intestinal infections has demonstrated its safety. Part of this good safety profile is also one of its potential limitations. Orally administered thiazolides, once absorbed by intestinal epithelial cells and distributed to the circulation, are rapidly inactivated in the liver and can thus not target anymore GSTP1-expressing cells elsewhere in the body. Primary intestinal epithelial cells, including the intestinal epithelial stem cells at the bottom of the crypts, show only low levels of GSTP1 expression, and are thus probably insensitive to thiazolides. However, it is very likely that orally administered thiazolides can efficiently target primary tumors of the intestine, which express very high levels of GSTP1 and have direct access to luminal thiazolides. Of particular interest in this regard is our observation that thiazolides strongly synergize with TRAIL and chemotherapeutic drugs in inducing apoptosis in colorectal tumor cells lines. Oral treatment of tumor patients may sensitize colorectal tumor cells to systemically administered chemotherapeutic drugs or TRAIL, and thereby allow to treat patients with lower doses of these drugs with less side effects on uninvolved tissues.
In summary, we here demonstrate a novel role for GSTP1 in the induction of thiazolide-mediated apoptosis in colorectal tumor cells via a JNK-and Bimdependent pathway. Our data further show that thiazolides strongly synergize with conventional antitumor drugs by sensitizing tumor cells. Given their minimal known side effects, thiazolides are promising candidates for future therapeutic treatment of primary colorectal tumors.
Materials and methods
Tissue culture reagents, biochemicals and pharmacological compounds All chemicals were from Sigma-Aldrich (Buchs, Switzerland) unless stated otherwise. The thiazolide RM4819 was synthesized at the Department of Chemistry and Biochemistry, University of Berne and kept as 10 mM stock solution in DMSO at À80 1C. The colon cancer cell lines Caco2 (ATCC HTB-37), HT29 (ATCC HTB-38), LS174T (ATCC CCL-188) and Colo205 (ATCC CCL-222) were from American Type Culture Collection (ATCC, Manassas, VA, USA). Cells were cultured in Iscove's Modified Dulbecco's Media supplied with 10% fetal calf serum, 50 mg/ml gentamicin at 37 1C and 5% CO 2 . Recombinant TRAIL was kindly provided by S. Frese, Bern, cisplatin was obtained from Sandoz (Cham, Switzerland), doxorubicine and CPT-11 from Pfizer (New York, NY, USA), JNK V Inhibitor and p38 inhibitor SB202190 were obtained from Calbiochem (Merck Chemical Ltd, Nottingham, UK), MEK inhibitor UO126 was obtained from Alexis Biochemicals (Enzo Life Sciences, Farmingdale, NY, USA).
Plasmids
The myc/his-tagged-GSTP1*A plasmid was generated by PCR-cloning human GSTP1 (GeneID: 2950) into a pcDNA3.1(A) þ vector (Invitrogen, Carlsbad, CA, USA) using the BamHI and XhoI restriction sites and the primers: fw 5 0 -TTTGGATCCACCGCCATGCCGCCCTACACC-3 0 , rev, 5 0 -CCGCTCGAGCTGTTTCCCGTTGCCATTGAT-3 0 . The expression plasmid for dominant-negative JNK 1 (DN JNK 1) was provided by Vicki Wa¨tzig and Thomas Herdegen University of Kiel, Germany. The expression plasmid for Bcl-2 was from Cyrill Rentsch, Department for Clinical Research, Berne, and the expression plasmid for Mcl-1 from Christoph Borner, Albert-Ludwigs-University, Freiburg, Germany.
The single nucleotide polymorphic variant GSTP1*B (Watson et al., 1998) was generated from the myc/his-GSTP1*A plasmid by mutating A313A to A313G using the QuikChange Site-directed Mutagenesis Kit from Stratagene (Agilent Technologies, Santa Cruz, CA, USA) using the following primers: fw 5 0 -CTCCGCTGCAAATACGTCTCCC TCATCTAC-3 0 , rev 5 0 -GTAGATGAGGGAGACGTATTT GCAGCGGAG-3 0 . Positive clones of GSTP1*A and GS TP1*B were verified by sequencing. For purification of recombinant GSTP1 protein GSTP1*A and GSTP1*B cDNAs were subcloned into pET 151/D-TOPO expression vector (Invitrogen), transformed into Escherichia coli BL21D3 and induced by 1 mM IPTG. Recombinant GSTP1 protein was purified by Ni 2 þ -Sepharose affinity chromatography, and enzymatic activity was determined as described previously (Muller et al., 2008b) .
The AP-1 reporter construct was generated by cloning six canonical AP-1 consensus sequences (TGAGTCA) (Strahl et al., 1997) into the pGL3 vector (Promega, Madison, WI, USA) using the following primers: fw 5 0 -AAGCTTTGATG AGTCAGCCGGCTGACTCATCATGATGAGTCAGCCAG G-3 0 , rev 5 0 -AAGCCTGGCTGACTCATCATGATGAGTCA GCCGGCTGACTCATCAAAG-3 0 . Self-annealing of the primers led to double-stranded DNA fragments with two AP-1 consensus sequences, a canonical HindIII restriction site at the 5 0 -end and an incomplete HindIII restriction site at the 3 0 -end, respectively. The incomplete HindIII restriction site was competent for ligation, but incompetent for subsequent digestion. Three consecutive fragments were ligated into the multiple cloning region of a pGL3 luciferase vector leading to a 6xAP-1 reporter construct (later described as 6xAP1-RE-LUC). The 0.8-kb reporter construct for the human bim promoter has been described previously (Badmann et al., 2011) .
AP-1 and Bim promoter assays AP-1 reporter or Bim reporter constructs, and b-galactosidase expression vectors were co-transfected into Caco2 and LS174T cells using the lipofection method (MIRUS TransIT LT-1, Mirus Bio LLC, Madison, WI, USA). In some experiments cells were co-transfected with dominant-negative JNK 1 expression vector. The amount of total transfected DNA was normalized with the corresponding empty vector plasmid. After 24 h, cells were cultured in 24-well plates and stimulated with various concentrations of RM4819 as indicated. In some experiments, cells were preincubated with 2 mM JNK V Inhibitor or DMSO for 30 min. After 8 h of stimulation, cells were lysed, and b-galactosidase and luciferase activity were measured as described previously (Mueller et al., 2007) .
DNA fragmentation assay
Stimulated and unstimulated cells were collected from 24-well plates and stained with hypotonic propidium iodide solution (100 mg/ml propidium iodide in 0.5 Â PBS pH7.4, 0.1% Triton-X100) for 30 min on ice (Nicoletti et al., 1991) . Then, DNA content was analyzed by flow cytometry (FACScan, BD Biosciences, San Jose, CA, USA) and evaluated using the FlowJo software (Ashland, OR, USA). Nuclei in the Sub-G0 fraction were considered apoptotic.
Annexin staining assay Caco2 and HT29 were transfected with expression plasmids such as GSTP1, Bcl-2 or Mcl-1 or the corresponding empty control vector as indicated. To track transfected cells, green fluorescence protein was co-transfected. After 24 h, cells were stimulated for additional 16 h with RM4819 or DMSO. Then cells were stained with biotinylated Annexin V (1:400) and Streptavidin-PE/Cy5 (1:200, Biolegends, San Diego, CA, USA) as previously described (Kasibhatla et al., 1998) . Annexin V staining on GFP-positive cells was measured by flow cytometry and analyzed by the FlowJo software.
DEVD cleavage assay
Cells were cultured in 24-well plates and stimulated as described above. After 16 h, cells were collected and lyzed in PBS, 1% Triton-X 100. Caspase activity was determined using an Ac-DEVD-AFC protease assay (BD Pharmigen, San Jose, CA, USA), as indicated by the supplier, and measured on a spectrofluorometer (Spectramax M2e, Sunnyvale, CA, USA) at 400 nm excitation and 505 nm emission wavelength.
Western blot
Cells were stimulated as indicated and lysed at indicated time points in PBS, 1% Triton X-100, and protease and phosphatase inhibitors (Roche, Basel, Switzerland). Lysates were separated on denaturating SDS-PAGE gels and transferred to PVDF membranes (Millipore, Billerica, MA, USA). Membranes were probed with antibodies against phosphorylated JNK, phosporylated p38 and phosphorylated ERK (all from Cell Signaling Technology, Davers, MA, USA), Bid (kindly provided by Thomas Kaufmann, Berne, Switzerland), Bim (Sigma-Aldrich) and Tubulin (Sigma-Aldrich). Primary antibodies were detected with corresponding horseradish peroxidase-labeled secondary antibodies and visualized by chemiluminescence on a LAS4000 (Fujifilm, Dielsdorf, CH, Switzerland).
RNA interference
Caco2 cells were plated in 6-well plates and transfected with 15 nM siControl (Dharmacon, siGenome SMARTpool D-001820-01), siGSTP1 (L-011179-00), siBim (L-004383-02), siBid (L-004387-00) or the combination thereof using HiperFect transfection reagent (Qiagen, Valencia, CA, USA) for 72 h. Cells were then cultured in 24-well plates and subsequently stimulated with RM4819 as indicated. The efficacy of knockdown was analyzed after 72 h by quantitative RT-PCR for GSTP1, and by western blot for Bim and Bid.
Mitochondrial isolation LS174T cells were cultured in 6-well plates, and treated with 12 ng/ml TRAIL or 10 mg/ml cisplatin in the presence or absence of 10 mM RM4819. After 8 and 16 h, cells were collected and fractionated for cytosolic or mitochondrial compartments, as described previously (Schneider-Jakob et al., 2010) . Cytosolic and mitochondrial lysates were then for cytochrome c, SMAC/Diablo and tubulin by western blot. Visceral Surgery and Medicine, Inselspital, Bern University Hospital, University of Bern, Switzerland. All patients provided informed consent and experiments were reviewed by an institutional review board. Tissue samples from the tumor center, the tumor edge and non-cancerous normal mucosa, B10 cm from the tumor edge, were collected. Total RNA was isolated and the expression of GSTP1 was analyzed by quantitative PCR on an Applied Biosystems Real-time PCR 7500 machine using SYBR green and Quantitect primer assays (Qiagen, Valencia, CA, USA). Gene expression was normalized by tubulin RNA levels and plotted as relative mRNA levels.
Immunohistochemistry for GSTP1
Tissue sections from primary and metastatic colon cancer were deparaffinized and rehydrated. Antigen retrieval was performed by boiling sections for 10 min in 10 mM citrate pH 6.0 in a pressure cooker (Jakob et al., 2008) . Then, endogenous peroxidase was blocked (Peroxidase Blocking Reagents, DakoCytomation) and GSTP1 expression was detected using an antihuman GSTP1 antibody (Sigma-Aldrich, Prestige Antibodies, 1:1000) and biotinylated secondary goat anti-rabbit IgG (SigmaAldrich, 1:200). Bound antibodies were detected by the streptavidin-biotin method (ABC-kit, Vectastain, Vector Laboratories, Reactolab, Servion, Switzerland) and visualized by DAB (Sigma). Sections were counterstained with Mayer's hematoxylin. The negative controls were performed by incubation with equal concentrations of normal rabbit IgG.
Detection of intracellular glutathione levels
Endogenous glutathione (GSH) levels were measured by monochlorobimane staining as described (Webb et al., 2006) .
Statistical analysis
Statistical differences in data sets were analyzed by two-tailed Student's t-test for experiments with two independent groups, and by ANOVA for experiments with three or more independent groups. Repetitive measurements were determined using Bonferroni correction. P-values of o0.05 were considered as significant.
